Objective: Vertical transmission of hepatitis C virus (HCV) infection is uncommon and occurs in approximately 5% of births from HCV-infected mothers. The reason for the low transmission rate is unclear. We aimed to investigate whether there is evidence of HCV exposure also in the noninfected children born to HCV-infected mothers by the presence of a detectable immune response. Methods: Serum and peripheral blood mononuclear cells from 9 HCV vertically infected children, 32 uninfected children born to HCV infected mothers, and 15 HCV chronically infected mothers, were analyzed. HCV-RNA-negative adults and children were used as controls. HCV-specific T cell responses were analyzed by interferon gamma using an enzyme-linked immunospot assay and 3H-thymidine incorporation assay. HCV antibodies were also analyzed. Results: An HCV-specific T cell response was detected in 73% (11/15) of the HCV-infected mothers, 67% (6/9) of the vertically infected children, 56% (18/32) of the exposed but uninfected children and in 10% and 20% of the control groups, respectively. The 2 groups of HCV-exposed children both had a significantly higher proportion of HCV-specific T cell responders compared to pediatric controls (P ¼ 0.01 and P ¼ 0.02). Conclusions: HCV-specific immune responses were more common in children born to HCV-infected mothers, regardless of the presence of HCV RNA. We conclude that noninfected children born to HCVinfected mothers may have been exposed to HCV antigens.
S
ince the introduction of blood donor screening for hepatitis C virus (HCV) infection, the major route of HCV infection in children is vertical transmission (HCV-VT) from mother to infant during pregnancy or delivery (1) (2) (3) . The rate of vertical transmission is low and estimated to be approximately 5% (1, 3, 4) , but increases up to approximately 20% in women who are coinfected with human immunodeficiency virus (1, 3) . The exact timing of transmission is not well understood, but it has been suggested that approximately one-third of HCV-VT events occur during pregnancy and the rest during delivery or the peripartal period (5) . There is currently no available effective intervention to prevent HCV-VT.
The mechanisms explaining the relatively low HCV-VT rate remain unknown. It has been hypothesized that children who are exposed to HCV antigens in utero may be endowed with some sort of protective immunity (6, 7) . Previous in vitro studies have shown that vertical exposure to HCV induces viral specific cell-mediated immune (CMI) responses in uninfected children of mothers with HCV infection (6) (7) (8) . The aims of this study were to investigate whether an HCV-specific immune response is present in uninfected but exposed children of HCV-infected mothers, how it develops over time, and whether it correlates to the risk of vertical HCV transmission.
What Is Known
Hepatitis C virus-specific cell-mediated immune responses have been detected in exposed but uninfected individuals in close contact with hepatitis C virus-infected persons. Hepatitis C virus-specific cell-mediated immune responses may play a role in the low risk of vertical transmission.
What Is New
We detected Hepatitis C virus-specific cell-mediated immune responses in uninfected children of Hepatitis C virus-infected mothers already in the newborn period, suggesting a pre-or perinatal exposure to viral antigens. The frequency and magnitude of the cell-mediated immune response were similar to that detected in vertically infected children and persist up to at least 2 years of age.
METHODS

Study Population
The study population consisted of 1 group of 15 HCV-RNApositive/human immunodeficiency virus-negative mothers and their 21 children followed prospectively from birth, of whom 2 were infected, as well as a cross-sectional group of 13 uninfected (HCV-RNA-negative and HCV-antibody-negative) children born to chronically HCV-infected (HCV-RNA-and HCV-antibody-positive) mothers and another cross-sectional group of 7 vertically HCVinfected children/adolescents (HCV-RNA and HCV-antibody positive) (See Supplemental Figure, Supplemental Digital Content 1, http://links.lww.com/MPG/B119, which describes the enrolled groups of patients). The cross-sectional groups of patients were added to increase the study population and to obtain study subjects of different ages. Blood from 10 HCV-RNA-and HCV-antibodynegative adult blood donors and cord blood from 10 newborns (born of HCV-antibody negative mothers) were used as adult and pediatric control groups, respectively.
Blood samples from the mothers were collected at 1 time point within 0 to 7 months post partum. In the prospectively studied group, blood samples from their children were collected consecutively at 1, 2, or 3 time points at approximately 0, 6, and 18 months of age. In the cross-sectional groups, blood samples from the uninfected group of 13 children were collected at 1 time point between 18 and 27 months of age and samples from the group of 7 HCV vertically infected children were collected at 1 time point at study inclusion (at ages 1, 1, 2, 6, 11, 15, 19 years, respectively). Vertical infection was defined by the detection of 2 positive HCV-RNA blood tests within a period of at least 6 months and the same viral genotype as in the mother.
All blood samples were analysed within 24 hours after venous puncture, using peripheral blood mononuclear cells (PBMC's) isolated from fresh whole blood. Informed written consent was obtained from all participants and/or their parents and the study was approved by the local ethics committee.
Virological Analyses
The anti-HCV, HCV-RNA, and NS3 IgG antibody analyses are described in detail in Supplemental Digital Content 2 (http:// links.lww.com/MPG/B120).
Recombinant Proteins and Peptides
Recombinant HCV proteins were pooled as NS3 and NS4 protein (3 mg/mL each), recombinant Core protein (3 mg/mL), recombinant NS5A, and NS5B protein (3 mg/mL each), or a mixture of all proteins (rNS3, rNS4, rCore, rNS5A, rNS5B [3 mg/mL each]). See Supplemental Digital Content 3 (http://links.lww.com/MPG/ B121), which describes the method in detail.
Enzyme-linked Immunospot Assay
A positive cut-off value for adults and children (<2 years' old) was calculated from the enzyme-linked immunospot (ELISpot) results of the adult and pediatric negative control groups, respectively, and defined as mean spot forming units (SFU)/10 6 PBMC in test wells-negative control wells þ 3 Â SD. The cut-off was set at >46 SFU/10 6 cells for adults and >31 SFU/10 6 cells for children younger than 2 years. The cut-off value of >46 SFU/10 6 PBMC was used for children older than 2 years (9) (See Supplemental Digital Content 4, http://links.lww.com/MPG/B122, which describes the method in detail).
3H Thymidine Incorporation Assay
A positive cut-off stimulation index (SI) was calculated from the adult control group and defined as mean SI þ 3 Â SD and set at SI >2.80. As the positive cut-off level is calculated from a quotient, there was no need for a specific child control group. The adult control group was then used as comparison for both mothers and children (See Supplemental Digital Content 5, http://links.lww.com/ MPG/B123, which describes the method in detail).
Statistical Analyses
Statistical analysis of nonparametrical data was analyzed using the Mann-Whitney U test. Comparison of proportions was performed by the Fisher exact test. Median regression analysis was performed to investigate relationships between predictors and outcome. A 2-sided significance level was set at P < 0.05. Statistical analyses were performed by using GraphPad Prism 7 (GraphPad Software, San Diego, CA) and STATA 13 (Stata Corporation, College Station, TX) softwares.
RESULTS
An overall HCV-specific T cell response, defined as a positive interferon gamma (IFNg) ELISpot response and/or a positive HCV-specific proliferation assay result to at least 1 HCV antigen, was detected in 73% (11/15) of the HCV-infected mothers, 56% (18/32) of the uninfected but exposed children, 67% (6/9) of the vertically infected children, and in 20% (2/10) of the adult negative control group, and 10% (1/10) of the pediatric negative control group (Fig. 1A) . The group of uninfected but exposed children and the vertically infected group of children both had a significantly higher proportion of HCV-specific T cell responders compared to the pediatric control group (P ¼ 0.01 and P ¼ 0.02, respectively). The proportion of T cell responders in the uninfected but exposed group was 60% before the age of 3 months, increased up to 75% by 6 months of age and then decreased to 56% by 24 months of age. For the last age group, older children from the cross-sectional cohort were included in the analysis. In the adult group, mothers had a significantly higher proportion of responders compared to the control group (P ¼ 0.01) (Fig. 1A) . Two of the children in the prospective group were found to be vertically infected with positive HCV-RNA test at the age of 1 and 3 months respectively. The clinical characteristics of the study population are shown in the Table 1 . Regression analysis did not reveal any other significant predictor for the outcome HCV-specific IFNg production or HCV-specific T cell proliferation.
Hepatitis C Virus-specific Interferon g Responses
IFNg production in response to HCV antigens was tested by ELISpot in 12 of the mothers, 9 of the vertically infected children, 30 of the uninfected/exposed children, 10 child controls, and 10 adult controls. The ELISpot analysis failed in 3 mothers and in another 2 cases of uninfected/exposed children (controls did not reach preset criteria) and was subsequently impossible to repeat because of lack of extra blood material. The proportion of IFNg responders in the group of uninfected/exposed children (53%, 16/ 30) was similar to the group of infected children (56%, 5/9). The uninfected/exposed group had a statistically significant higher proportion of responders compared to the child control group (P ¼ 0.03) and both groups of children had a higher proportion of IFNg responders compared to the mothers (42%, 5/12) and the adult controls (10%, 1/10) (Fig. 1B) . The intensity of HCV-specific IFNg production did not differ between the pediatric groups and the controls. The HCV-infected mothers produced a stronger IFNg response toward HCV antigens compared to the uninfected groups of children and adults (Fig. 1C) . We also noted a significantly higher number of children in both the uninfected/exposed group and the vertically infected group with an IFNg response towards multiple HCV antigen pools compared to the child controls (P ¼ 0.04 and P ¼ 0.02 respectively) (Fig. 1D) . The result from the NS3 antibody detection analysis is shown in Supplemental Digital Content 6 (http://links.lww.com/MPG/B124).
Hepatitis C Virus-specific T Cell Proliferation
HCV-specific T cell proliferation was analysed by 3H-Thymidine incorporation after recall with HCV antigens. The same pools of HCV proteins and peptides as in the ELISpot analysis were used. HCV-specific proliferation was analysed in 15 mothers, 9 vertically infected children, 24 exposed/uninfected children and 10 adult controls. There were not enough cells to run the proliferation analysis in 8 cases of exposed/uninfected children owing to a limited amount of drawn blood. A significantly higher proportion of infected mothers had an HCV specific T cell FIGURE 1. The proportion of overall HCV-specific T cell responders in the groups of patients (defined as a positive interferon g enzyme-linked immunospot response and/or a positive proliferation assay response to at least 1 HCV antigen) (A), the proportion of interferon g enzyme-linked immunospot responders (B), the cumulative interferon g response (expressed as mean spot forming units (SFU)/10 6 cells, error bars representing median þ interquartile range (C), and the positive interferon g response to the number of different antigen pools (D). The cut-off for a positive interferon g response was set at >46 SFU/10 6 cells for patients >2 years and >31 SFU/10 6 cells for children <2 years. HCV ¼ hepatitis C virus, SFU ¼ spot forming units.
proliferative response compared to the controls (53% vs 10%, P ¼ 0.04), whereas no significant difference was noticed between the pediatric groups (uninfected/exposed 7/24, 29% vs infected 3/9, 33%) and the controls (10%, 1/10) ( Fig. 2A) . There was no statistically significant difference in the level of the proliferative response between the groups (Fig. 2B) . In contrast to the IFNg production, there was no significant difference in the multispecific T cell proliferative response (toward >1 antigen pool) between the pediatric groups; however, mothers had a broader proliferative T cell response than controls (P ¼ 0.01) (Fig. 2C) .
DISCUSSION
Vertical transmission of HCV is rare and the reason for this is not clear. Various immunological factors thought to have an effect on HCV-VT have previously been studied. Interferon lambda 4 (IFNL4) and interferon lambda 3 (IFNL3) (also named interleukin 28B ) are associated with interferon treatment response and spontaneous clearance of HCV (10, 11) . We and others have recently shown that the INFL3 genotype does not seem to influence the risk of HCV-VT (12, 13) . Maternal-infant human leukocyte antigen (HLA) mismatch and various HLA types have been associated with a decreased risk of HCV-VT (14-16). The phenotype and number of natural killer cells also seem to be of importance to the risk of HCV-VT (16, 17) . Interestingly, post-partum control of HCV in mothers has been associated with T cell responses influenced by interleukin 28B and HLA genotypes (18) . There are few studies on the role of HCV-specific T cells in HCV-VT. Della Bella et al (6) found a high proportion (71%) of HCV-specific T cell responders in a group of vertically exposed but uninfected children. In another similar study, a lower frequency (14%) of HCV-specific CMI responses in exposed/uninfected children but a high frequency (80%) of CMI responses in a transiently viremic group of children was reported (8) . Children in those 2 studies were tested from 1 year of age.
In the present study, we found that the proportion of children with HCV-specific T cell responses was almost as high in uninfected children prenatally exposed to maternal HCV as in vertically infected children (56% and 67%, respectively) and significantly higher than in unexposed controls (P ¼ 0.01). The immune responses were mainly HCV-specific IFNg recall responses to HCV antigens and were not always linked to HCV-specific T cell proliferation. The magnitude and breath of the IFNg response in the uninfected/exposed children was comparable to the response of the vertically infected group.
We included and tested children from birth and were able to detect HCV-specific T cell responses in 60% of uninfected/exposed children by the age of 3 months. Such an early T cell response suggests exposure of HCV antigens during pregnancy or at the time of delivery. Consequently, the frequency of pre-and perinatal HCV exposure may be higher than previously reported. HCV-specific CMI responses in seronegative and nonviremic individuals have been described in populations at risk for HCV exposure, such as healthy family members (19) , siblings of infected children (20) , spouses (21) , health care workers (22) , and people who inject drugs (23) .
The HCV-exposed children (both infected and uninfected) elicited a statistically significant broader IFNg response toward HCV antigens as compared to controls. A broad multispecific IFNg response toward HCV antigens has been associated with higher frequency of spontaneous resolution (24) . Antibodies against HCV nonstructural proteins do not yield protective immunity and presence of maternal neutralizing antibodies is not associated with decreased risk of vertical HCV infection (25, 26) . Specific antibodies toward the NS3 protein have been shown to persist for a long time in successfully treated patients (27) . We found that 64% of children in the uninfected/exposed group had NS3 antibody titers of at least 1/360. This further supports an early exposure to HCV antigens. We were able to detect an HCV-specific immune response in children until the age of approximately 2 years (ie, at the end of the study period) after exposure in the majority of uninfected children. Previous studies have shown that HCV-specific CMI responses are detectable up to 4 to 8 years after birth in children of HCV-infected mothers (6, 8) .
It is currently not possible to determine whether the HCVspecific immune responses seen in exposed but uninfected children are protective against HCV infection, or just a sign of previous encounter with the virus. Studies on HCV-specific CMI responses in individuals at high risk for HCV infection have shown that they may be partially protected from chronic infection, and that reinfection in CMI responders yielded a shortened viremia period (28) (29) (30) (31) (32) (33) . Studies in chimpanzees have shown that HCV-specific CMI responses were associated with spontaneous clearance and protection from chronic reinfection (34) (35) (36) . Other studies, however, suggest that HCV infection primes weak immune responses in humans (37) and animal models (38, 39) .
Our study has some limitations mainly because of a small sample size, although comparable to the few previous studies (6, 8) . The mean age differed between our studied pediatric groups, which may be of importance because the immune response in newborns and small children is considered immature. We tried to compensate for this by including a control group of cord blood from healthy newborns and from this group we calculated a different cut-off for the neonates. It is possible, however, that we would have detected a difference in the magnitude of the immune response between the infected and exposed/uninfected group if the infected group of children had been younger. It has been described previously that cross-reactivity against influenza virus or human herpes virus 1 may yield false-positive CMI responses (40, 41) . We cannot completely rule out cross-reactivity in our study; however, the frequency of cross-reacting T cell responses would then be similar in all groups. The frequency of multispecific responses to several HCV antigens in the exposed and infected groups also makes the risk of falsepositive results less likely. Cross-reactivity or unknown previous exposure to low-dose HCV antigens cannot be excluded in the 2 adult controls with positive reactions. This is, however, unlikely in the cord blood control where a possible explanation may be unspecific background reactivity, which is taken into consideration when comparing the groups.
In conclusion, we were able to detect HCV-specific CMI responses in uninfected children of HCV-infected mothers already in the newborn period, which suggest a pre-or perinatal exposure to viral antigens. The frequency and magnitude of the CMI response were similar to that detected in vertically infected children and it persist up to at least 2 years of age. The immune response was not stronger or broader in the uninfected/exposed children compared to the vertically infected children, suggesting that strong CMI responses are not enough to protect from vertical transmission. Larger prospective studies with longer follow-up are needed to determine whether HCV-specific CMI responses in exposed but uninfected children are protective or not.
